HMGA2 overexpression in non-small cell lung cancer
| Autor: | Thomas Weigel, Torsten Goldmann, Jörn Bullerdiek, Martin Sandkamp, Siegfried Loeschke, Ekkehard Vollmer, Anke Schultze, Britta Meyer |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
Cancer Research Lung Neoplasms Adenocarcinoma HMGA2 Carcinoma Non-Small-Cell Lung Biomarkers Tumor medicine Carcinoma Humans RNA Messenger Lung cancer Lung Molecular Biology Aged Cause of death biology Reverse Transcriptase Polymerase Chain Reaction HMGA2 Protein Cancer Middle Aged medicine.disease Gene Expression Regulation Neoplastic medicine.anatomical_structure Immunology Carcinoma Squamous Cell biology.protein Cancer research Immunohistochemistry Female |
| Zdroj: | Molecular Carcinogenesis. 46:503-511 |
| ISSN: | 1098-2744 0899-1987 |
| DOI: | 10.1002/mc.20235 |
| Popis: | Lung cancer is still the leading cause of death from cancer worldwide primarily because of the fact that most lung cancers are diagnosed at advanced stages. Overexpression of the high mobility group protein HMGA2 has been observed in a variety of malignant tumors and often correlates with poor prognosis. Herein, HMGA2 expression levels were analyzed in matching cancerous and non-cancerous lung samples of 17 patients with adenocarcinoma (AC) and 17 patients with squamous cell carcinoma (SCC) with real-time quantitative RT-PCR (qRT-PCR). Transcript levels were compared to results obtained by immunohistochemistry (IHC). HMGA2 expression was detectable by qRT-PCR in all samples tested and varied from 5422 to 16 991 545 copies per 250 ng total RNA in the carcinoma samples and from 289 to 525 947 copies in the non-cancerous tissue samples. In 33/34 non-small cell lung cancer (NSCLC) samples tested, an overexpression of HMGA2 was revealed with statistically highly significant differences between non-neoplastic and tumor samples for both AC (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text